ClinConnect ClinConnect Logo
Search / Trial NCT05050253

Lavage With Super-Oxidized Solution for Secondary Peritonitis

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Sep 9, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Secondary Peritonitis Emergency Abdominal Surgery Super Oxidized Solution Surgical Site Infection Mortality

ClinConnect Summary

This clinical trial is studying a new treatment for a serious abdominal condition called secondary peritonitis, which can occur after issues like a perforated organ or an infection. The researchers want to find out if washing the abdominal cavity with a special solution, known as super-oxidized solution (SOS), can help reduce the risk of infections and death in patients undergoing emergency surgery for this condition. The hope is that using this solution will lead to better outcomes for patients facing this medical emergency.

To participate in the trial, individuals must be over 18 years old and scheduled for emergency abdominal surgery due to secondary peritonitis. They should not be pregnant or have certain types of peritonitis that are not the focus of this study. Participants can expect to receive careful monitoring during and after their treatment. By joining this trial, they have the chance to contribute to important research that could improve care for future patients with similar conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Secondary peritonitis due to suspected hollow viscus perforation, anastomotic insufficiency, and/or abdominal abscess (including patients with the named abdominal emergencies as a complication after elective surgery)
  • Scheduled emergency abdominal surgery by laparotomy with peritoneal lavage
  • Age over 18 years
  • Written informed consent
  • Exclusion Criteria
  • Pregnancy (will be ruled out using beta-hCG testing in women of childbearing potential)
  • Patients with primary or tertiary peritonitis

About Insel Gruppe Ag, University Hospital Bern

Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.

Locations

Bern, , Switzerland

Patients applied

0 patients applied

Trial Officials

Tobias Haltmeier, MD

Principal Investigator

Inselspital, Bern University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials